Recent Investment Analysts’ Ratings Updates for Structure Therapeutics (GPCR)

A number of research firms have changed their ratings and price targets for Structure Therapeutics (NASDAQ: GPCR):

• 8/17/2026 – Structure Therapeutics was upgraded by Wall Street Zen from “strong sell” to “sell”.
• 8/9/2026 – Structure Therapeutics was downgraded by Wall Street Zen from “sell” to “strong sell”.
• 8/7/2026 – Structure Therapeutics was given a new $111.00 price target by Canaccord Genuity Group Inc..
• 8/7/2026 – Structure Therapeutics had its “market outperform” rating reaffirmed by Citigroup Inc..
• 8/7/2026 – Structure Therapeutics had its price target lowered by Citigroup Inc. from $100.00 to $97.00. They now have a “buy” rating on the stock.
• 8/7/2026 – Structure Therapeutics had its price target lowered by Citizens Jmp from $113.00 to $110.00. They now have a “market outperform” rating on the stock.
• 8/1/2026 – Structure Therapeutics was upgraded by Wall Street Zen from “strong sell” to “sell”.
• 7/17/2026 – Structure Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.